TED · VERIFIED SOURCE

Czechia – Immunosuppressive agents – Selektivní imunosupresiva - Ravulizumab III.

Institut klinické a experimentální medicíny · Czechia · Praha

352,260,000 CZK

Deadline 2026-11-10

Open official source ↗
BUSINESS NEED

Opportunity details

Procurement notice published by Institut klinické a experimentální medicíny.

BUYER

Institut klinické a experimentální medicíny

Open the buyer profile to see mapped decision responsibilities and other active needs.

View buyer profile

Provenance

Provider: TED · External ID: 690837-2026 · Published 2026-10-06 22:00:00

Official source ↗